Summary
The 2 major factors affecting serum levels of the most commonly used cardiac glycoside digoxin, are patient compliance and the physical characteristics of the tablet; the latter is unimportant with the lipid soluble glycosides digitoxin and β-methyldigoxin. Several drugs interfere with the absorption of these cardiac glycosides from the gastrointestinal tract, either by adsorption, altering gut motility or other unknown mechanisms, but only mixtures containing kaolinpectin (and possibly some liquid antacids) are of potential clinical importance with tablets of a satisfactory dissolution profile.
Enzyme inducing agents can increase the rate of elimination of digitoxin and heparin-induced free fatty acid release decrease protein binding of digitoxin, but the therapeutic implications are not clear.
The biological action on the heart depends on the amount of glycoside in the myocardial tissue and the reaction of the patient’s diseased heart to the drug. Experimental work on tissue glycoside concentration is of great fundamental interest but of unknown clinical relevance, except for digoxin antibodies which are the most specific remedy for poisoning in attempts at suicide.
In the absence of specific electrocardiographic changes in digitalis overdosage, estimation of serum concentrations are mandatory. The role of hypokalaemia in digitalis toxicity is, in the author’s opinion, controversial but the role of some drugs in altering myocardial sensitivity to cardiac glycosides is important.
Interest in drug interactions with cardiac glycosides was initially raised by studies conducted in New York by Lindenbaum et al. (1971) who showed that serum digoxin levels in patients varied widely and were dependent on the particular brand of digoxin tablet. About this time, a senior hospital physician was under my care with uncontrolled atrial fibrillation; treatment with the hospital 0.25mg tablet of digoxin resulting in a zero plasma digoxin level (Binnion, 1974a). In this very practical way, we were lead into exploring factors affecting the bioavailability of digoxin. Bioavailability is concerned with the amount of a drug reaching the systemic circulation from a dosage form and has been investigated very extensively in the case of digoxin.
The term digitalis refers to steroid or steroid glycoside compounds that exert typical positive inotropic and electrophysiological effects on the heart. Over 300 compounds with these characteristics exist and all contain a steroid nucleus with a 5-or 6-membered unsaturated lactone ring attached to the C17 position (fig. 1). The double-bond of the lactone ring is essential for cardiac action, the structural requirements for activity are present in aglycones (e.g. digitoxigenin) and the addition of one or more sugar moieties at position C3modifies potency and duration of action, but not the fundamental pharmacological properties of this class of compound (Henderson, 1969).
Similar content being viewed by others
References
Baskin, S.I.; Dutta, S. and Marks, B.H.: The effects of diphenylhydantoin and potassium on the biological activity of ouabain in the guinea-pig heart. British Journal of Pharmacology 47: 85–96 (1973).
Bazzano, G. and Bazzano, G.S.: Digitalis intoxication — Treatment with a new steroid-binding resin. Journal of the American Medical Association 220: 828–830 (1972).
Becker, D.J.; Nonkin, P.M.; Bennett, L.D.; Kimball, S.G.; Sternberg, M.S. and Wasserman, F.: Effect of isoproterenol on digitalis cardiotoxicity. American Journal of Cardiology 10: 242–247 (1962).
Beermann, B.: The gastrointestinal uptake of methyldigox-in-12α-3H in man. European Journal of Clinical Pharmacology 5: 28 (1972).
Beermann, B.; Hellstrom, K. and Rosen, A.: Fate of orally administered 3H-digitoxin in man with special reference to absorption. Circulation 43: 852–861 (1971).
Beermann, B.; Hellstrom, K. and Rosen, A.: The absorption of orally administered [12α-3H] digoxin in man. Clinical Science 43: 507–518 (1972).
Beermann, B.; Hellstrom, K. and Rosen, A.: The gastrointestinal absorption of digoxin in seven patients with gastric or small intestinal reconstructions. Acta Medica Scandinavica 193: 293–297 (1973).
Beller, G.A.; Smith, T.W.; Abelmann, W.H.; Haber, E. and Hood, W.B.: Digitalis intoxication. New England Journal of Medicine 284: 989–997 (1971).
Bigger, J.T. and Strauss, H.C.: Digitalis toxicity: drug interactions promoting toxicity and the management of toxicity. Seminars in Drug Treatment 2: 147–177 (1972).
Binnion, P.F. and McDermott, M.: Bioavailability of digoxin. Lancet ii: 592 (1972).
Binnion, P.F.: Absorption of different commercial preparations of digoxin in the normal human subject, and the influence of antacid, antidiarrhoeal and ion-exchange resins; in Storstein (Ed) Symposium on Digitalis, p.216–224 (Gyldendal Norsk Förlag, Oslo, Norway 1973a).
Binnion, P.F.: Zero plasma digoxin levels in patients on oral digoxin therapy. Irish Journal of Medical Science 148: 346–349 (1974a).
Binnion, P.F.: The absorption of digoxin tablets. Clinical Pharmacology and Therapeutics 16: 807–812 (1974b).
Binnion, P.F.; McDermott, M. and LeSher, D.: Bioavailability of digoxin. Lancet 1: 1118 (1973).
Binnion, P.F.: A comparison of the bioavailability of digoxin in capsule, tablet, and solution taken orally with intravenous digoxin. J. Clin. Pharmacol. 16: 461–467 (1976).
Binnion, P.F. and Das Gupta, R.: Tritiated digoxin metabolism after prior treatment with propranolol or diphenylhydantoin sodium. International Journal of Clinical Pharmacology 12: 96–101 (1975).
Brown, D.D. and Juhl, R.P.: Decreased bioavailability of digoxin due to antacids and kaolin pectin. New England Journal of Medicine 295: 1034–1037 (1976).
Butler, V.P.: Assay of digitalis in the blood. Progress in Cardiovascular Disease 14: 571–600 (1972).
Butler, V.P. and Chen, J.P.: Digoxin-specific antibodies. Proceedings of the National Academy of Sciences 57: 71–78 (1967).
Butler, V.P.; Schmidt, D.H.; Smith, T.W.; Haber, E.; Raynor, B.D. and Demartini, P.: Effect of Fab Fragments of Sheep Antidigoxin Antibody on serum concentrations and urinary excretion of digoxin. Circulation 48 (Suppl.): 130 (1973).
Caldwell, J.H. and Greenberger, N.J.: Cholestyramine enhances digitalis excretion and protects against lethal intoxication. Journal of Clinical Investigation 49: 16a (1970).
Caldwell, J.H. and Greenberger, N.J.: Interruption of the enterohepatic circulation of digitoxin by cholestyramine. Journal of Clinical Investigations 50: 2626–2637 (1971).
Caldwell, J.H.; Martin, J.F.; Dutta, S. and Greenberger, N.J.: Intestinal absorption of digoxin-3H in the rat. American Journal of Physiology 217: 1747–1751 (1969).
Curry, P.; Fitchett, D.; Stubbs, W. and Krikler, D.: Ventricular arrhythmias and hypokalaemia. Lancet 2: 231–233 (1976).
Das Gupta, R. and Binnion, P.F.: Tissue digoxin concentrations at digoxin intoxication in normal, acutely hypokalemic, and acutely hyperglycemic dogs. Physiological Chemistry and Physics 8: 207–220 (1976).
Doherty, J.E.; Hall, W.H.; Sherwood, J.; Girkin, D. and Gammill, J.: Serum protein binding of digoxin in human subjects; in Storstein (Ed) Symposium on Digitalis, p.48–54 (Gyldendal Norsk Forlag, Oslo, Norway 1973).
Dunbar, R.W.; Boettner, R.B.; Gatz, R.N.; Pennington, R.E. and Morrow, D.H.: The effect of mepivacaine, bupivacaine and lidocaine on digitalis-induced ventricular arrhythmias. Anesthesia and Analgesia Current Researches 49: 761–766 (1970).
Evered, D.C. and Chapman, C.: Plasma digoxin concentrations and digoxin toxicity in hospital patients. British Heart Journal 33: 540–545 (1971).
Fisch, C. and Knoebel, S.B.: Recognition and therapy of digitalis toxicity. Progress in Cardiovascular Diseases 13: 71–96 (1970).
Frye, R. and Braunwald, E.: Studies on digitalis III. The influence of triiodothyronine on digitalis requirements. Circulation 23: 376–382 (1961).
Greenberger, N.J.; MacDermott, R.P.; Martin, J.F. and Dutta, S.: Intestinal absorption of six tritium-labelled digitalis glycosides in rats and guinea pigs. Journal of Pharmacology and Experimental Therapeutics 167: 265–273 (1969).
Greenblatt, D.J.; Duhme, D.W.; Koch-Weser, J. and Smith, T.W.: Evaluation of digoxin bioavailability in single-dose studies. New England Journal of Medicine 289: 651–654 (1973).
Greenblatt, D.J.; Duhme, D.W.; Koch-Weser, J. and Smith, T.W.: Intravenous digoxin as a bioavailability standard: slow infusion and rapid injection. Clinical Pharmacology and Therapeutics 15: 510–513 (1974).
Greenblatt, D.J.; Smith, T.W. and Koch-Weser, J.: Bioavailability of drugs: the digoxin dilemma. Clinical Pharmacokinetics 1: 36–51 (1976).
Hall, W.M. and Doherty, J.E.: Tritiated digoxin XXII. Absorption and excretion in malabsorption syndromes. American Journal of Medicine 56: 437–442 (1974).
Hall, W.H.; Shappell, S.D. and Doherty, J.E.: Effect of cholestyramine on digoxin absorption and excretion in man. American Journal of Cardiology 39: 213–216 (1977).
Hartel, G.; Manninen, V. and Reisell, P.: Treatment of digoxin intoxication. Lancet 2: 158 (1973).
Heizer, W.D.; Smith, T.W. and Goldfinger, S.E.: Absorption of digoxin in patients with malabsorption syndromes. New England Journal of Medicine 285: 257–259 (1971).
Heifant, R.H.; Scherlag, B.J. and Damato, A.N.: The electrophysiological properties of diphenylhydantoin sodium as compared to procaine amide in the normal and digitalis-intoxicated heart. Circulation 36: 108–118 (1976a).
Heifant, R.H.; Scherlag, B.J. and Damato, A.N.: Protection from digitalis toxicity with the prophylactic use of diphenylhydantoin sodium. Circulation 36: 119–124 (1967b).
Henderson, F.G.: Chemistry and biological activity of the cardiac glycosides; in Fisch and Surawicz (Eds) Digitalis, p.3–12 (Grune and Stratton, New York 1969).
Hoeschen, R.J.: The effect of digoxin antibody on the washout of tritiated digoxin and its inotropic effect from perfused rabbit hearts; in Roy and Dhalla (Eds) Recent Advances in the Study of Cardiac Structure and Metabolism, p.345–353 (University Park Press, Baltimore 1976).
Iisalo, E.: Clinical pharmacokinetics of digoxin. Clinical Pharmacokinetics 2: 1–16 (1977).
Jounela, A.J.; Pentikainen, P.J. and Sothmann, A.: Effect of particle size on the bioavailability of digoxin. European Journal of Clinical Pharmacology 8: 365–370 (1975).
Juhl, R.P.; Summers, R.W.; Guillory, J.K.; Blaug, S.M.; Cheng, F.H. and Brown, D.D.: Effect of sulphasalazine on digoxin bioavailability. Clinical Pharmacology and Therapeutics 20: 387–400 (1976).
Khalil, S.A.H.: The uptake of digoxin and digitoxin by some antacids. Journal of Pharmacy and Pharmacology 26: 961–967 (1974).
Kleiger, R.E.; Vitale, J. and Lown, B.: Clinical and experimental relationships between digitalis and potassium. Proceedings of the New England Cardiovascular Society 23: 19–21 (1964-1965).
Larbig, D.; Scheler, F.; Schmidt, H.J.; Betzien, G. and Kaufmann, B.: Untersuchungen zur enteralen Resorption von β-methyl-digoxin. (Investigations into the enterai absorption of β-methyl digoxin). Klinische Wochenschrift 49: 604–607 (1971).
Lahiri, K. and Ertel, N.: Mechanism of diphenylhydantoin (DPH) induced decrease in serum digoxin (DG) levels. Clinical Research 22: 321A (1974).
Lindenbaum, J.; Maulitz, R.M. and Butler, V.P.: Inhibition of digoxin absorption by neomycin. Gastroenterology 71: 399–404 (1976).
Lindenbaum, J.; Maulitz, R.M.; Saha, J.R.; Shea, N. and Butler, V.P.: Impairment of digoxin absorption by neomycin. Clinical Research 20: 410 (1972).
Lindenbaum, J.; Mellow, M.H.; Blackstone, M.O. and Butler, V.P.: Variation in biologic availability of digoxin from four preparations. New England Journal of Medicine 285: 1344–1347 (1971).
Lucchesi, B.R. and Shivak, R.: Effect of quinidine and procaine amide upon acetylstrophanthidin cardiotoxicity. Journal of Pharmacology and Experimental Therapeutics 143: 366–373 (1964).
Lukas, D.S.: The pharmacokinetics and metabolism of digitoxin in man; in Storstein (Ed) Symposium on Digitalis, p.84–102 (Gyldendal Norsk Förlag, Oslo, Norway 1973).
Lukas, D.S. and DeMartino, A.G.: Binding of digitoxin and some related cardenolides to human plasma proteins. Journal of Clinical Investigation 48: 1041–1053 (1969).
Manninen, V.; Apajalahti, A.; Melin, J. and Karesoja, M.: Altered absorption of digoxin in patients given propantheline and metoclopramide. Lancet 1: 398–400 (1973a).
Manninen, V.; Apajalahti, A.; Simonen, H. Reissell, P.: Effect of propantheline and metoclopramide on absorption of digoxin. Lancet 1: 1118–1119 (1973b).
Marcus, F.I.: Metabolism of digoxin in normal man and factors influencing the body distribution; in Storstein (Ed) Symposium on Digitalis, p. 112–125 (Gyldendal Norsk Förlag, Oslo, Norway 1973).
Marcus, F.I.; Kapadia, G.G. and Goldsmith, C.: Alteration of the body distribution of tritiated digoxin by acute hyperkalemia in the dog. Journal of Pharmacology and Experimental Therapeutics 165: 136–148 (1969).
Marcus, F.I.; Quinn, E.J.; Horton, H.; Jacobs, S.; Pippin, S.; Stafford, M. and Zukoski, C.: The effect of jejunoileal bypass on the pharmacokinetics of digoxin in man. Circulation 55: 537–541 (1976).
Mason, D.T.; Zelis, R.; Lee, G.; Hughes, J.L.; Spann, J.F. and Amsterdam, E.A.: Current concepts and treatment of digitalis toxicity. American Journal of Cardiology 27: 545–559 (1971).
Morgan, L.M. and Binnion, P.F.: The distribution of 3H-digoxin in normal and acutely hyperkalaemic dogs. Cardiovascular Research 4: 235–241 (1970).
Morrow, D.H. and Townley, N.T.: Anesthesia and digitalis toxicity: an experimental study. Anesthesia and Analgesia Current Researches 43: 510–519 (1964).
Morrow, D.T.; Gaffney, T.E. and Braunwald, E.: Studies on digitalis VII. Influence of hyper- and hypothyroidism on the myocardial response to ouabain. Journal of Pharmacology and Experimental Therapeutics 140: 324–328 (1963).
Okita. G.T.: Relationship between Na+, K+-ATPase inhibition and the inotropic and cardiotoxic actions of digitalis; in Storstein (Ed) Symposium on Digitalis, p.131–143 (Gyldendal Norsk Forlag, Oslo, Norway 1973).
Perrier, D.; Mayersohn, M. and Marcus, F.I.: Clinical pharmacokinetics of digitoxin. Clinical Pharmacokinetics 2: 292–311 (1977).
Sampson, J.J.; Alberton, E.C. and Kondo, B.: Effects on man of potassium administration in relation to digitalis glycosides with special reference to blood potassium, electrocardiogram and ectopic beats. American Heart Journal 26: 164–179 (1943).
Shaw, T.R.D. and Carless, J.E.: The effect of particle size on the absorption of digoxin. European Journal of Clinical Pharmacology 7: 269–273 (1974).
Solomon, H.M.: Interaction of digitoxin with other drugs; in Storstein (Ed) Symposium on Digitalis, p.324–329 (Gyldendal Norsk Förlag, Oslo, Norway 1973).
Smith, T.W.; Haber, E. and Yeatman, L.: Reversal of advanced digoxin intoxication with Fab fragments of digoxin-specific antibodies. New England Journal of Medicine 294: 797–800 (1976).
Steiness, E.: Renal tubular secretion of digoxin. Circulation 50: 103–107 (1974).
Steiness, E. and Olesen, K.H.: Cardiac arrhythmias induced by hypokalaemia and potassium loss during maintenance digoxin therapy. British Heart Journal 38: 167–172 (1976).
Storstein, L.: Protein binding of cardiac glycosides in disease states. Clinical Pharmacokinetics 2: 220–233 (1977).
Sumner, D.J. and Russell, A.J.: Digoxin pharmacokinetics and multicompartmental analysis and its clinical implications. British Journal of Clinical Pharmacology 3: 221–229 (1976).
Thompson, W.G.: Relationship of in vitro binding of digoxin to its intestinal absorption in rats. Canadian Journal of Pharmacology 51: 832–834 (1973).
van Bever, R.J.; Duchateau, A.M.J.A.; Pluym, B.F.M. and Merkus, F.W.H.M.: The effect of colestipol on digitoxin plasma levels. Arzneimittel-Forschung 26: 1891–1893 (1976).
Vaughan Williams, E.M. and Sekiya, A.: Prevention of arrhythmias due to cardiac glycosides by block of β-sympathetic receptors. Lancet 1: 420–421 (1963).
Vohringer, H.F.; Kuhlmann, J. and Rietbrock, N.: Der einfluss von antacida auf die plasmakonzentration von digoxin beim menschen. Deutsche Medizinische Wochenschrift 101: 106–108 (1976).
Wilkinson, P.R.; Hesp, R.; Issler, H. and Raftery, E.D.: Total body and serum potassium during prolonged thiazide therapy for essential hypertension. Lancet 1: 759–762 (1975).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Binnion, P.F. Drug Interactions with Digitalis Glycosides. Drugs 15, 369–380 (1978). https://doi.org/10.2165/00003495-197815050-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-197815050-00003